Faculty Profiles - ARIMA, Hiroshi

Papers - ARIMA, Hiroshi

Division display 161 - 180 of about 294 ／ All the affair displays >>

免疫チェックポイント阻害薬(ICIs)関連内分泌障害発症例では全生存率が延長する

小林朋子, 岩間信太郎, 奥地剛之, 岡田則男, 安田康紀, 有馬寛

日本内科学会雑誌 Vol. 108 ( Suppl. ) page： 226 - 226 2019.2

Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease Reviewed International journal

Ozeki Takaya, Katsuno Takayuki, Hayashi Hiroki, Kato Sawako, Yasuda Yoshinari, Ando Masahiko, Tsuboi Naotake, Hagiwara Daisuke, Arima Hiroshi, Maruyama Shoichi

AMERICAN JOURNAL OF NEPHROLOGY Vol. 49 ( 1 ) page： 54 - 63 2019

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: In pediatric patients with steroid-sensitive nephrotic syndrome, recent trials have revealed that a 2-month, short-term steroid regimen is not inferior to an extended steroid course. However, the optimal duration of initial steroid therapy for adult steroid-sensitive minimal change disease (MCD) remains unclear. OBJECTIVES: The aim of present study was to evaluate the effectiveness of a 2-month, short-term steroid regimen in the treatment of adult steroid-sensitive MCD patients. METHOD: This was a prospective observational study. Adult patients with steroid-sensitive MCD (n = 35) who were initiated on a short-term steroid regimen between January 2015 and June 2016 were included. The details of the regimen are as follows: (1) prednisolone was administered at an initial dose of 0.8-1.0 mg/kg/day and continued for 4-6 weeks and (2) dosage was reduced to 0.5-0.6 mg/kg/alternate day and continued for 4 weeks. Control patients (n = 140), who were treated using conventional steroid administration, were selected from our previous adult MCD cohort. All patients fulfilled the following criteria: biopsy-proven MCD, age ≥20 years, first episode of nephrotic syndrome, and attainment of complete remission within 4 weeks. The following parameters of patients who received short-term treatment regimen and control patients were compared: any relapse and frequent relapse, adverse events caused by steroid treatment and cumulative steroid dose. RESULTS: Throughout the observation period (median: 17.3 months), 24 (68.6%) patients in the short-term group developed at least one relapse. The short-term regimen showed earlier occurrence of any relapse than the conventional regimen (adjusted hazard ratio [aHR] 2.45; 95% CI 1.51-3.97; p < 0.001), but there was no difference in frequent relapse (aHR 1.31; 95% CI 0.43-3.99; p = 0.63). None of the patients showed any symptoms of adrenal insufficiency after discontinuation of corticosteroids. The cumulative steroid dose during the observational period was significantly lower in the short-term group than in the conventional group. CONCLUSIONS: The short-term steroid regimen may represent an effective treatment option that ensures lower steroid exposure when treating adult steroid-sensitive MCD patients.

DOI： 10.1159/000495352

Web of Science

PubMed

Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis Reviewed

Yasuda Yoshinori, Iwama Shintaro, Arima Hiroshi

ENDOCRINE JOURNAL Vol. 66 ( 3 ) page： 271 - 275 2019

Authorship：Last author Language：English Publishing type：Research paper (scientific journal)

Primary sclerosing cholangitis (PSC) has been known as a cause of secondary osteoporosis, which often requires medication. Herein, we give the first report of a case of a 38-year-old man with fatigue and paralysis in both upper limbs who had been treated with denosumab for secondary osteoporosis associated with PSC. Since bisphosphonate (alendronate) was ineffective in our patient, the treatment was changed from alendronate to denosumab. Despite replacements with calcium and active vitamin D (alfacalcidol; 1-hydroxycholecalciferol), he developed severe hypocalcemia (albumin-adjusted serum calcium: 5.2 mg/dL) 2 weeks after the second administration of denosumab, which required immediate correction. After that, the corrected serum calcium levels were controlled within the normal range with 0.75 μg of eldecalcitol (1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3) and increased doses of calcium (1,500 mg daily) and phosphate (900 mg daily) without denosumab. Even though denosumab treatment had been terminated, the T score of the lumbar spine improved from -4.4 to -2.6 by 1 year after the second administration, possibly due to the amelioration of osteomalacia through the treatment with eldecalcitol and the higher doses of calcium and phosphate. This report indicates that denosumab can cause severe hypocalcemia in patients with osteoporosis associated with chronic diseases of the hepatobiliary system including PSC, in turn suggesting that the possibility of vitamin D deficiency or osteomalacia should be considered before administering treatments and that serum calcium levels should be closely monitored to detect life-threatening hypocalcemia in patients who have high risk factors for hypocalcemia.

DOI： 10.1507/endocrj.EJ18-0545

Web of Science

PubMed

Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.

Hiroshi Arima, Shintaro Iwama, Hidefumi Inaba, Hiroyuki Ariyasu, Noriko Makita, Michio Otsuki, Kazunori Kageyama, Akihisa Imagawa, Takashi Akamizu

Endocrine journal Vol. 66 ( 7 ) page： 581 - 586 2019

Language：English Publishing type：Research paper (scientific journal)

Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve, and endocrine organs. Endocrine irAEs comprise hypopituitarism, primary adrenal insufficiency, thyroid dysfunction, hypoparathyroidism, and type 1 diabetes mellitus. These conditions have the potential to lead to life-threatening consequences, such as adrenal crisis, thyroid storm, severe hypocalcemia, and diabetic ketoacidosis. It is therefore important that both endocrinologists and oncologists understand the clinical features of each endocrine irAE to manage them appropriately. This opinion paper provides the guidelines of the Japan Endocrine Society and in part the Japan Diabetes Society for the management of endocrine irAEs induced by ICIs.

DOI： 10.1507/endocrj.EJ19-0163

Web of Science

PubMed

ペムブロリズマブ使用中止2ヵ月後に1型糖尿病を発症した一例

岡田則男, 岩間信太郎, 半田朋子, 奥地剛之, 小林朋子, 安田康紀, 恒川卓, 有馬寛

日本内分泌学会雑誌 Vol. 94 ( 3 ) page： 976 - 976 2018.12

マウスES細胞視床下部分化誘導系後期に残存するRax+細胞はTanycytesと類似する

加納麻弓子, 須賀英隆, 有馬寛

日本内分泌学会雑誌 Vol. 94 ( 4 ) page： 1319 - 1319 2018.12

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Reviewed

Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y

Cancer science 2018.9

高脂肪食の継続投与はグリア細胞の極性変化を伴い視床下部炎症が増悪する

杉山摩利子, 坂野僚一, 柳沼裕史, 滝啓吾, 溝口暁, 恒川卓, 高木博史, 伊藤禎浩, 小峯起, 山中宏二, 有馬寛

肥満研究 Vol. 24 ( Suppl. ) page： 185 - 185 2018.9

傍鞍部腫瘍術後遅発性低Na血症の発症と予防法の検討

竹内和人, 川端哲平, 永田雄一, 秋禎樹, 石川隆之, 高木博史, 有馬寛, 若林俊彦

日本内分泌学会雑誌 Vol. 94 ( Suppl.HPT ) page： 37 - 40 2018.9

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：(一社)日本内分泌学会

当院で傍鞍部腫瘍に対しeTSS(内視鏡下経鼻経蝶形骨手術)を施行した98例(男性50例、女性48例、平均年齢55.9歳)を対象に、術後の遅発性低Na血症(DHN)発症について検討した。その結果、DHNは37例(37.8%)に認められた。DHN発症患者ではDHN発症時のAVP分泌が抑制されていないことが確認された。また、術後7日目においてDHN非発症患者では約3%程度の体重低下を認めるのに対し、DHN発症例では体重減少は1%程度と軽微であり、体内への水分貯留が示唆された。術前より尿崩症が認められた患者群ではDHN発症が少なかったものの、DHN発症例では渇感中枢障害を伴っていた。これは術後の脱水を危惧したADH補充による医原性のものと考えられた。以上、傍鞍部腫瘍の術後DHNの発症にはSIADHが強く関与していることが考えられた。尚、術後早期からの水分制限はDHN発症予防に有効と考えられたが、より適切なプロトコールならびに予測法の確立が必要である。

Chemical chaperone 4-phenylbutylate reduces mutant protein accumulation in the endoplasmic reticulum of arginine vasopressin neurons in a mouse model for familial neurohypophysial diabetes insipidus International journal

Masayoshi Tochiya, Daisuke Hagiwara, Yoshinori Azuma, Takashi Miyata, Yoshiaki Morishita, Hidetaka Suga, Takeshi Onoue, Taku Tsunekawa, Hiroshi Takagi, Yoshihiro Ito, Shintaro Iwama, Motomitsu Goto, Ryoichi Banno, Hiroshi Arima

Neuroscience Letters Vol. 682 page： 50 - 55 2018.8

Language：English Publishing type：Research paper (scientific journal) Publisher：Elsevier Ireland Ltd

Familial neurohypophysial diabetes insipidus (FNDI), characterized by progressive polyuria and loss of arginine vasopressin (AVP) neurons, is an autosomal dominant disorder caused by AVP gene mutations. Our previous studies with FNDI model mice demonstrated that mutant proteins accumulated in the endoplasmic reticulum (ER) of AVP neurons. Here, we examined therapeutic effects of the chemical chaperone 4-phenylbutylate (4-PBA) in FNDI mice. Treatment with 4-PBA reduced mutant protein accumulation in the ER of FNDI mice and increased AVP release, leading to reduced urine volumes. Furthermore, AVP neuron loss under salt loading was attenuated by 4-PBA treatment. These data suggest that 4-PBA ameliorated mutant protein accumulation in the ER of AVP neurons and thereby prevented FNDI phenotype progression.

DOI： 10.1016/j.neulet.2018.06.013

Web of Science

Scopus

PubMed

Functional adenosine triphosphate-sensitive potassium channel is required in high-carbohydrate diet-induced increase in β-cell mass. Reviewed

2018.8

A novel mechanism of autophagy-associated cell death of vasopressin neurons in familial neurohypophysial diabetes insipidus. Invited Reviewed

Hagiwara D, Grinevich V, Arima H

Cell and tissue research 2018.6

Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. Reviewed

Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, Shibata T, Ohashi N, Izumi K, Nishie W, Shimizu H, Arima H, Sobajima H

Journal of diabetes investigation 2018.6

Association of pre-existing thyroid autoimmunity with the development of thyroid dysfunction induced by nivolumab. Reviewed

Kimbara, S; Fujiwara, Y; Iwama, S; Ohashi, K; Kuchiba, A; Arima, H; Yamazaki, N; Kitano, S; Yamamoto, N; Ohe, Y

JOURNAL OF CLINICAL ONCOLOGY Vol. 36 ( 15 ) 2018.5

Functional Pituitary Tissue Generation from Human Embryonic Stem Cells. Reviewed International journal

Kano M, Suga H, Kasai T, Ozone C, Arima H

Current protocols in neuroscience Vol. 83 ( 1 ) page： e48 2018.4

Language：English Publishing type：Research paper (scientific journal)

The anterior pituitary gland produces several hormones essential for regulation of the somatic endocrine system. Deficiency of these hormones can cause life-threatening diseases, including adrenal crisis. Pituitary tissue generated from human pluripotent stem cells is expected to provide better treatment than current hormone replacement therapy. During early mammalian development, the pituitary anlage (Rathke's pouch) develops from non-neural ectoderm adjacent to the developing ventral hypothalamus. The close interaction between these two tissues is crucial for Rathke's pouch development and involves several signaling molecules. Early exposure of human embryonic stem cells in 3D floating culture to sonic hedgehog and bone morphogenetic protein 4 promoted the cells' differentiation into oral ectoderm and, subsequently, hormone-producing cells such as corticotrophs (adrenocorticotropic hormone-producing cells). The differentiation approach described herein, which induces the formation of pituitary tissue in contact with hypothalamic neural tissue, mimics mammalian pituitary development. The differentiated corticotrophs are functional, responding normally to both release and feedback signals. © 2018 by John Wiley & Sons, Inc.

DOI： 10.1002/cpns.48

PubMed

ニボルマブ誘発破壊性甲状腺炎の発症率は甲状腺自己抗体陽性者で有意に高い

小林朋子, 岩間信太郎, 岡田則男, 安田康紀, 有馬寛

日本内分泌学会雑誌 Vol. 94 ( 1 ) page： 420 - 420 2018.4